Table 4 Selected immunophenotypic profiles in prior studies
Hoefnagel et al9 | Hoefnagel et al8 | Goodlad et al15 | Kodama et al11 | Senff et al16 | Xie a | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
PCFCL | DLBCL-LT | PCFCL | DLBCL-LT | DLBCL b | DLBCL-LT | PCFCL | DLBCL-LT | PCFCL | DLBCL-LT | PCFCL | DLBCL-LT | |
BCL6 | 23/23 | 19/19 | ND | ND | 12/17 | 7/13 | 41/44 | 30/40 | 122/132 | 30/44 | 22/22 | 3/10 |
CD10 | 1/24 | 0/19 | ND | ND | 8/17 | 2/13 | 7/39 | 2/33 | 9/141 | 0/47 | 7/22 | 3/10 |
BCL2 | 2/24 | 17/19 | ND | ND | 8/17 | 13/13 | 10/44 | 40/40 | 16/148 | 44/49 | 9/22 | 10/10 |
MUM-1 | ND | ND | 0/5 | 11/11 | ND | ND | 3/43 | 22/29 | 13/128 | 36/40 | 11/22 | 8/10 |
HGAL | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | 15/17 | 3/9 |
